BeOne Medicines (ONC) Non-Current Deffered Revenue (2017 - 2023)

BeOne Medicines (ONC) has 6 years of Non-Current Deffered Revenue data on file, last reported at $300000.0 in Q4 2023.

• Quarterly Non-Current Deffered Revenue fell 99.29% year-over-year to $300000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $300000.0 (down 99.29% YoY) and the FY2023 annual result came in at $300000.0, down 99.29% from the prior year.
• Non-Current Deffered Revenue steadied at $300000.0 in Q4 2023 per ONC's latest filing, from $300000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $220.3 million in Q4 2021 and bottomed at $300000.0 in Q3 2023.
• The 4-year median for Non-Current Deffered Revenue is $52.3 million (2021), against an average of $81.6 million.
• The widest annual swing landed in 2022, when Non-Current Deffered Revenue jumped 186.77%; it then tumbled 99.8% in 2023.
• Tracing ONC's Non-Current Deffered Revenue over 4 years: stood at $8.2 million in 2019, then jumped by 2573.41% to $220.3 million in 2021, then tumbled by 80.92% to $42.0 million in 2022, then slumped by 99.29% to $300000.0 in 2023.
• Per Business Quant, the three latest ONC Non-Current Deffered Revenue figures stand at $300000.0 (Q4 2023), $300000.0 (Q3 2023), and $24.3 million (Q2 2023).

Peer Comparison